Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Exciting Myeloma Announcements and What to Watch For at ASH 2015 with Dr. Ola Landgren, MD, PhD, MSKCC

Posted on: Nov 20, 2015

Play Episode

Also available on

Spotify

Apple Podcasts

Youtube

Description

Dr. Ola Landgren, MD, PhD Memorial Sloan Kettering Cancer Center Interview Date: November 20, 2015

Two new drugs were announced in a single week for myeloma treatment and the pace is ever increasing. Dr. Ola Landgren at Memorial Sloan Kettering Cancer Center shares more about the recent daratumumab and ixazomib announcements. He also shares trends from a recent myeloma expert conference in Rome - giving the best therapy possible for newly diagnosed patients up front, using minimal residual disease (MRD) to make sure that happened and using good drugs for relapse, which can potentially have the same outcomes as a newly diagnosed patient. He also tells us what to watch for at ASH - the French study of upfront vs. delayed transplant, the pipeline of new drugs, the CAR T cell immunotherapy work and many other topics. Dr. Landgren reviews the clinical trials that are open at MSKCC (links provided below) and the wide range of research that is happening to further improve outcomes for myeloma patients. Clinical Trials Discussed in This Show Ixazomib, the new oral proteasome inhibitor with allo transplant for high-risk patients Pomalidomide and dex with or without ixazomib Higher Carfilzomib Doses without Transplant Smoldering Myeloma Daratumumab VLX1570 - an upstream proteasome inhibitor The Myeloma Crowd Radio Show With Dr. Ola Landgren

This episode sponsored by Takeda Oncology

Overview

Dr. Ola Landgren, MD, PhD Memorial Sloan Kettering Cancer Center Interview Date: November 20, 2015

This episode sponsored by Takeda Oncology

On this episode

C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Transcript

Exciting Myeloma Announcements and What to Watch For at ASH 2015 with Dr. Ola Landgren, MD, PhD, MSKCC

Related Content